Former IRS Commissioner Danny Werfel and the AICPA are teaming up to form a new group to advance responsible AI use in both tax administration and practice.
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.
Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.
Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey the hardest-hit state.
The Public Company Accounting Oversight Board won a consolidated John Doe case that claimed the PCAOB’s disciplinary proceedings violated two auditors’ constitutional rights.